NCT01002937

Brief Summary

The purpose of this project is to analyze tumour tissue from a group of subjects with renal cell carcinoma, who have been treated at the Royal Marsden Hospital.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
182

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2008

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2008

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

October 27, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 28, 2009

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 17, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 17, 2014

Completed
Last Updated

June 18, 2024

Status Verified

June 1, 2024

Enrollment Period

6 years

First QC Date

October 27, 2009

Last Update Submit

June 14, 2024

Conditions

Renal Cell Carcinoma

Keywords

BiomarkersPrognosis response to treatmentRenal cancer

Outcome Measures

Primary Outcomes (1)

  • The profiling of the expression of signal transduction biomarkers, gene expression, gene copy numbers and effect of mutations of the VHL gene in renal cancer and their relationship to clinical outcomes.

    5 years

Study Arms (1)

Tumour tissue, renal cell carcinoma

\> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Tumour tissue from subjects with renal cell carcinoma, who have been treated at the Royal Marsden Hospital

You may qualify if:

  • The presence of histologically proven renal cell cancer
  • The availability of paraffin embedded tissue
  • Informed consent needed for tissue taken after January 2006 (date of enforcement of human tissue act)

You may not qualify if:

  • Absence of histological tissue
  • Absence of consent to study tissue after January 2006

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Royal Marsden NHS Foundation Trust

Sutton, Surrey, SM2 5PT, United Kingdom

Location

MeSH Terms

Conditions

Carcinoma, Renal CellKidney Neoplasms

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Professor Martin Gore

    Royal Marsden NHS Foundation Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor Martin Gore

Study Record Dates

First Submitted

October 27, 2009

First Posted

October 28, 2009

Study Start

December 1, 2008

Primary Completion

December 17, 2014

Study Completion

December 17, 2014

Last Updated

June 18, 2024

Record last verified: 2024-06

Locations

GB(1)